Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor

Drug Metabolism and Disposition

Volumn 24, Issue 3, 1996, Pages 307-314

  Chiba, Masato ^a   Hensleigh, Michelle ^a   Nishime, Joy A ^a   Balani, Suresh K ^a   Lin, Jiunn H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DIETHYLDITHIOCARBAMIC ACID; FURAFYLLINE; INDINAVIR; KETOCONAZOLE; MEPHENYTOIN; PROTEINASE; QUINIDINE; SULFAPHENAZOLE; TROLEANDOMYCIN;

ANTIVIRAL ACTIVITY; ARTICLE; COMPETITIVE INHIBITION; DRUG EFFECT; DRUG OXIDATION; DRUG PROTEIN BINDING; ENZYME ACTIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER MICROSOME METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN CROSS LINKING;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; HIV PROTEASE INHIBITORS; HUMANS; HYDROXYLATION; INDINAVIR; ISOENZYMES; KETOCONAZOLE; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; TROLEANDOMYCIN;

EID: 0029872126     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. J. P. Vacca, B. D. Dorsey, W. A. Schleif, R. B. Levin, S. L. McDaniel, P. L. Darke, J. Zugay, J. C. Quintero, O. M. Blahy, E. Roth, V. V. Sardana, A. J. Schlabach, P. I. Graham, J. H. Condra, L. Botlib, M. K. Holloway, J. H. Lin, I.-W. Chen, K., Vastag, D. Ostovic, P. S. Anderson, E. A. Emini, and J. R. Huff: L-735,524: an orally bioavailable HIV-1 protease inhibitor. Proc. Natl. Acad. Sci. U.S.A. 91, 4096-4100 (1994).
2. S. K. Balani, B. H. Arison, L. Mathai, L. R. Kauffman, R. R. Miller, R. A. Stearns, I.-W. Chen, and J. H. Lin: Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine. Drug Metab. Dispos. 23, 1-5 (1995).
3. F. P. Guengerich and T. Shimada: Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem. Res. Toxicol. 4, 391-407 (1991).
4. T. Omura and R. Sato: The carbon-monooxide binding pigment of liver microsomes. J. Biol. Chem. 239, 2370-2378 (1964).
5. O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall: Protein measurement with the Polin phenol reagent. J. Biol. Chem. 193, 265-275 (1951).
6. D. Sesardic, A. R. Boobis, B. P. Murray, S. Murray, J. Segura, R. De La Torre, and D. S. Davies: Furafylline is a potent and selective inhibitor of cytochrome P-450 IA2 in man. Br. J. Clin. Pharmacol. 29, 651-663 (1990).
7. K. L. Kunze and W. F. Trager: Isoform-selective mechanism-based inhibition of human cytochrome P-450 1A2 by furafylline. Chem. Res. Toxicol. 6, 649-656 (1993).
8. D. J. Back, J. F. Tjia, J. Karbwang, and J. Colbert: In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles. sulphonamides and quinolines. Br. J. Clin. Pharmacol. 26, 23-29 (1988).
9. J. O. Miners, K. J. Smith, R. A. Robson, M. E. McManus, M. E. Veronese, and D. J. Birkett: Tolbutamide hydroxylation by human liver microsomes. Kinetic characterization and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem. Pharmacol. 37, 1137-1144 (1988).
10. W. R. Brian, P. K. Srivastava, D. R. Umbenhauer, R. S. Loyd, and F. P. Guengerich: Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemistry 28, 4993-4999 (1990).
11. S. V. Otton, T. Inaba, and W. Kalow: Competitive inhibition of sparteine oxidation in human liver by β-adrenoreceptor antagonists and other cardiovascular drugs. Life Sci. 34, 73-80 (1983).
12. F. P. Guengerich, D.-H. Kim, and M Iwasaki Role of human cytochrome P-450 IIEI in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol. 4, 168-179 (1991).
13. P. B. Watkins, S. A. Wrighton, P Maurel, E. G. Schuetz, G. Mendez-Picon, G. A. Parker, and P, S. Guzellian: Identification of an inducible form of cytochrome P-450 in human liver. Proc. Natl. Acad. Sci. U.S.A. 82, 6310-6314 (1985).
14. M. Maurice, L. Pichard, M. Daujat, I. Fabre, H. Joyeux, J. Domergue, and P. Maurel: Effects of imidazole derivatives on cytochromes P-450 from human hepatocytes in primary culture. FASEB J. 6, 752-758 (1992).
15. P. K. Srivastava, C -H. Yun, P. H. Beaune, C. Ged. and F. P. Guengerich: Separation of human liver tolbutamine hydroxylase and (5)-mephenytoin 4′-hydroxylase cytochrome P-450 enzymes. Mol. Pharmacol. 40, 69-79 (1991).
16. F. J. Gonzalez, F. Vilbois, J. P. Hardwick, O. W. McBride, D. W. Nebert, H. V. Gelboin, and U. A. Meyer Human debrisoquine 4-hydroxylase (P-450 IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22. Genomics 2, 174-179 (1988).
17. T. Aoyama, S. Yamano, D. J. Waxman, D. P. Lapenson, U. A. Meyer, V. Fisher, T. Inaba, N. Kalow, H. Gelboin, and F. Gonzalez: Cytochrome P-450hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. J. Biol. Chem. 264, 10388-10395 (1989)
18. M. V. Relling, T. Aoyama, F. J. Gonzalez, and U. A. Meyen Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J. Pharmacol. Exp. Ther. 252, 442-447 (1990).
19. E. J. M. Reinerink, L. Doom, E. H. J. M. Jansen, and A. A. J. Van Iersel: Measurement of enzyme activities of cytochrome P-450 isoenzymes by high-performance liquid Chromatographic analysis of products. J. Chromatogr. 553, 233-241 (1991).
20. D. J. Newton, R. W. Wang, and A. Y. H. Lu: Cytochrome P-450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. 23, 154-158 (1995).
21. F.P. Guengerich: Oxidation of quimdine by human liver cytochrome P-450. Mol. Pharmacol. 30, 287-295 (1986).
22. S. Ward and D. J. Back: Metabolism of gestodene in human liver cytosol and microsomes in vitro. J. Steroid. Biochem. Mol. Biol 46, 235-243 (1993).
23. J. R. Cashman, Z. Yang, L. Yang, and S. A. Wrighton: Stereo and regioselective N- and S-oxidation of tertiary amines and sulfides in the presence of adult human liver microsomes. Drug Metab. Dispos. 21, 492-501 (1993).
24. F. P. Guengerich and C. G. Turvy : Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J. Pharmacol. Exp. Ther. 256, 1189-1194 (1991).
25. T. Shimada, H. Yamazaki, M. Mimura, Y. Inui, and F. P. Guengerich: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270, 414-423 (1994).
26. S. A. Wrighton and J. C. Stevens: The human hepatic cytochromes P-450 involved in drug metabolism. Crit. Rev. Toxicol, 22, 1-21 (1992).